From 2007 to 2013, the incidence of metastatic prostate cancer increased by 7.1% annually, resulting in a cumulative increase of 72% compared with 2004.
The investigational oral androgen receptor drug ODM-201 has significant antitumor activity with a favorable safety profile in men with metastatic castration-resistant prostate cancer, according to a pooled analysis of 2 early-phase clinical trials.
Is the Glass Half Empty or Half Full? First Study Compares Robotic-Assisted Surgery and Open Radical Prostatectomy
The first randomized trial to compare robotic-assisted prostatectomy with conventional open radical prostatectomy found no meaningful differences between these techniques in urinary and sexual function or in the rate of positive surgical margins in men with localized prostate cancer in the first 12 weeks after surgery (Yaxley JW, et al. Lancet.
IsoPSA, a New Biomarker Test, Differentiates High- and Low-Grade Prostate Cancer, Improves Diagnostic Accuracy
The IsoPSA assay holds promise for improved diagnostic accuracy, said Eric A. Klein, MD, Chairman, Glickman Urological and Kidney Institute, Cleveland Clinic, OH, at the 2016 American Urological Association annual meeting.
“A shorter, hypofractionated schedule of radiation is noninferior to conventional radiation for disease control in men with intermediate-risk prostate cancer at a median follow-up of 6 years,” said lead investigator Charles N. Catton, MD, FRCPC, Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada, who presented the study results.
“Redirecting radical prostatectomy patients to high-volume providers is associated with better medical and oncologic outcomes, shorter length of stay, and fewer complications. Referrals within 100 miles are not only feasible but could save significant societal costs,” said Sarmad Sadeghi, MD, PhD, of the USC Norris Comprehensive Cancer Center, Los Angeles, CA, who presented the study results.
Increased levels of physical activity after a diagnosis of prostate cancer are associated with significantly better survival, according to the results of a new, large prospective cohort study.
The regular use of aspirin reduces the incidence of and risk for death from lethal prostate cancer, according to the results of a large observational study reported at the 2016 ASCO Genitourinary Cancers Symposium.
A liquid biopsy using phlebotomy blood samples can identify phenotypes and genomic characteristics of circulating tumor cells that may personalize treatment selection for men with advanced prostate cancer.
A genomic classifier is now available that can predict a low or high risk for metastasis in men with prostate cancer who have rising prostate-specific antigen (PSA) after a prostatectomy. The good news is that this test is reimbursable by Medicare.
Page 1 of 3
Results 1 - 10 of 28
Results 1 - 10 of 28